CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are rare malignancies characterized by resistance to chemotherapy and poor clinical outcomes. While immunotherapy have shown promise, especially in the first-line treatment, effective therapeutic strategies for patients with PD-L1-negat...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ünal Metin Tokat, Şevval Nur Bilgiç, Ashkan Adibi, Esranur Aydın, Onur Tutar, Hilal Cansız, Ali Yılmaz Altay, Nalan Akgul Babacan, Eylül Özgü, Alina Melisa Manea, Mutlu Demiray
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2026-05-01
Series:	Frontiers in Immunology
Assuntos:	Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) immunotherapy CDK4/6 inhibitor precision oncology pembrolizumab ipilimumab
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1858358/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!